Luxturna was recently approved for the treatment of a blindness-causing RPE65 gene mutation. With two injections in each eye, patients diagnosed with a hereditary retinal dystrophy would be able to experience improved vision.
Luxturna was recently approved for the treatment of a blindness-causing RPE65 gene mutation. With two injections in each eye, patients diagnosed with a hereditary retinal dystrophy would be able to experience improved vision.